Nov 07, 2020
EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer's Disease (CTAD) Meeting
Oct 06, 2020
EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB)
Dec 05, 2019
EIP Pharma Announces Presentation of Phase 2b Clinical Trial Results of Neflamapimod in Early-stage Alzheimer's Disease at Clinical Trials in Alzheimer's Disease (CTAD) meeting
Nov 07, 2019
EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer's Disease
Nov 07, 2019
EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)
Aug 01, 2019
EIP Pharma to Present at Canaccord Genuity 39th Annual Growth Conference
Jul 17, 2019
EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38a Kinase Inhibitor Neflamapimod on the Neurodegenerative Process
Jul 12, 2019
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies
Jul 09, 2019
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Huntington's Disease
Jul 08, 2019
EIP Pharma Appoints Noel Donnelly as CFO
Apr 15, 2019
EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications
Dec 13, 2018
EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled
Oct 24, 2018
EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment